Skip to main content

Xenon Pharmaceuticals Inc(XENE-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low55.66
Day High57.00
Open:56.48
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Tipranks
Analysts Are Bullish on Top Healthcare Stocks: Xenon (XENE), Biogen (BIIB)
GlobeNewswire
Xenon Presents Azetukalner Phase 3 X-TOLE2 Study Results and 48-Month Long-term Data in Focal Onset Seizures at 2026 AAN Annual Meeting
Tipranks
Xenon to Spotlight Neurology Pipeline at Series of 2026 Investor Conferences
GlobeNewswire
Xenon to Present at Upcoming Investor Conferences
Tipranks
Xenon Expands 2025 Inducement Equity Incentive Plan
Tipranks
Xenon to Unveil Phase 3 Azetukalner Data and Pipeline Advances at 2026 AAN Meeting
GlobeNewswire
Xenon to Highlight Phase 3 X-TOLE2 & Long-Term Data for Azetukalner in Focal Onset Seizures at 2026 AAN Annual Meeting
Tipranks
Analysts Offer Insights on Healthcare Companies: Intensity Therapeutics, Inc. (INTS), IQVIA Holdings (IQV) and Xenon (XENE)
Motley Fool
Xenon Pharma Stock Up 55% as Insider Sells $78K in Shares. Here's What Investors Should Know
Zacks Investment Research
Xenon Pharmaceuticals Stock Soars 20% in 3 Months: Here's Why
Xenon Pharmaceuticals Stock Soars 20% in 3 Months: Here's Why
Tipranks
Analysts Offer Insights on Healthcare Companies: Xenon (XENE), Protagonist Therapeutics (PTGX) and CG Oncology, Inc. (CGON)
Tipranks
H.C. Wainwright Keeps Their Buy Rating on Xenon (XENE)
Tipranks
Xenon Sets Date for 2026 Annual Shareholder Meeting
Tipranks
Xenon’s X-TOLE2 Trial Completion Puts XEN1101 in Focus for Epilepsy Investors
Tipranks
Bank of America Securities Keeps Their Buy Rating on Xenon (XENE)
Tipranks
Xenon Strengthens Balance Sheet With Major Equity Offering
Motley Fool
This Fund Has a $200 Million Bet on a Biotech Stock Up 30% in Days After Phase 3 Breakthrough
Motley Fool
Battery Storage Stock Up 50% in a Year Draws New $110M Investment. Here's What You Should Know
Motley Fool
Biotech Stock Up 685% Draws $80.5 Million Investment Amid Dual FDA Filings
Tipranks
Stifel Nicolaus Sticks to Its Buy Rating for Xenon (XENE)
GlobeNewswire
Xenon Pharmaceuticals Announces Closing of $747.5 Million Upsized Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Tipranks
Xenon Raises $650 Million in Upsized U.S. Equity Offering
Tipranks
Wells Fargo Sticks to Their Buy Rating for Xenon (XENE)
GlobeNewswire
Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering
Tipranks
Xenon Pharmaceuticals Launches $500 Million Public Share Offering
Tipranks
Wall Street Analysts Are Bullish on Top Healthcare Picks
Zacks Investment Research
XENE Stock Up as Azetukalner Meets Goal in Focal Onset Seizures Study
XENE Stock Up as Azetukalner Meets Goal in Focal Onset Seizures Study
Tipranks
Analysts Are Bullish on Top Healthcare Stocks: MBX Biosciences, Inc. (MBX), REPRO-MED Systems (KRMD)
Tipranks
Xenon’s Azetukalner Hits Phase 3 Mark in Focal Onset Seizures, Paving Way for FDA Filing
Tipranks
Xenon Sets Date to Unveil Phase 3 Epilepsy Data for Lead Drug Azetukalner
GlobeNewswire
Xenon Pharmaceuticals Announces Proposed Public Offering
The Globe and Mail
Xenon stock soars as B.C. drug developer reports strong results for epilepsy treatment
Ian Mortimer, CEO of Xenon, poses for a photograph at the lab in Burnaby, B.C, on Friday, December 1, 2023. Tijana Martin/ The Globe and Mail

Profile

Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of medicines through the application of its proprietary discovery platform, which it refer to as Extreme Genetics. Xenon is developing proprietary product candidates for the treatment of both orphan as well as more prevalent diseases. The company offers Glybera (R), a gene therapy for the treatment of lipoprotein lipase deficiency, an orphan disorder. Xenon Pharmaceuticals Inc. is headquartered in Burnaby, Canada.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.